B4GALNT1 and cancer: The structure of B4GALNT1 allows for the prediction and testing of competitive inhibitors as potential therapeutics in diseases where overexpression is driving pathogenesis (such as cancers) or where GM2 substrate reduction would be beneficial (GM2 gangliosidoses).